ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "scleroderma and systemic sclerosis"

  • Abstract Number: 814 • 2018 ACR/ARHP Annual Meeting

    NON Diffuse SSc, Peripheral Neuropathy, Concomitant Sjogren Syndrome and ANTI-RNA Polymerase III Represent Risk Factors for the Higher Frequency of Cancer in a Large Single Cohort of Patients with Systemic Sclerosis

    Ana Paula Luppino-Assad1, Adriana Bortoluzzo2, Henrique Carriço da Silva3, Danieli Andrade4 and Percival Sampaio-Barros4, 1Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., sao paulo, Brazil, 2c Instituto Insper de Educação e Pesquisa, São Paulo, SP, Brasil, sao paulo, Brazil, 3Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., SAO PAULO, Brazil, 4Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., São Paulo, Brazil

    Background/Purpose: A higher prevalence of cancer has been described in patients with systemic sclerosis (SSc), but the magnitude of this risk and the type of…
  • Abstract Number: 903 • 2018 ACR/ARHP Annual Meeting

    Riociguat in Patients with Early Diffuse Cutaneous Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study (RISE-SSc)

    Oliver Distler1, Yannick Allanore2, Christopher P. Denton3, Masataka Kuwana4, Marco Matucci-Cerinic5, Janet E. Pope6, Janethe Pena7, Kaisa Laapas8, Zhen Yao9 and Dinesh Khanna10, 1Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 2Rheumatology A Department, Cochin Hospital, Paris Descartes University, Sorbonne Paris Cité, Paris, France, 3UCL Division of Medicine, Royal Free Campus, London, United Kingdom, 4Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 5Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 6Department of Medicine, University of Western Ontario, London, ON, Canada, 7Clinical Development, Bayer US LLC, Whippany, NJ, 8StatFinn Oy, Espoo, Finland, 9Bayer Healthcare Co. Ltd.,, Beijing, China, 10Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI

    Background/Purpose: There are few disease-modifying therapies for the treatment of systemic sclerosis (SSc), particularly the more severe diffuse cutaneous form (dcSSc). The soluble guanylate cyclase…
  • Abstract Number: 1108 • 2018 ACR/ARHP Annual Meeting

    Antibody Repertoire Dynamics in Systemic Sclerosis after Myeloablative Autologous Hematopoietic Stem-Cell Transplantation or Cyclophosphamide Treatment

    Julia Z. Adamska1,2, Leslie Crofford3, Daniel E. Furst4,5, Ellen Goldmuntz6, Lynette Keyes-Elstein7, Maureen D. Mayes8, Peter McSweeney9, Richard Nash9, Ashley Pinckney10, Beverly Welch11, Keith Sullivan12 and William H. Robinson1,2, 1Stanford University, Stanford, CA, 2VA Palo Alto Health Care System, Palo Alto, CA, 3Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, 4University of California Los Angeles, Los Angeles, CA, 5University of Washington, Seattle, WA, 6NIAID, NIH, Bethesda, MD, 7Clinical Statistics, Rho Federal Systems, Inc., Chapel Hill, NC, 8Rheumatology, University of Texas McGovern Medical School, Houston, TX, 9Colorado Blood Cancer Institute, Denver, CO, 10Rho Federal Systems, Inc., Chapel Hill, NC, 11National Institutes of Health, Bethesda, MD, 12Duke University Medical Center, Durham, NC

    Background/Purpose: Myeloablative autologous hematopoietic stem-cell transplantation (HSCT) was recently demonstrated to provide benefit over monthly cyclophosphamide (CYC) in the treatment of diffuse cutaneous systemic sclerosis…
  • Abstract Number: 1725 • 2018 ACR/ARHP Annual Meeting

    Fecal Microbiota Transplantation in Patients with Systemic Sclerosis- a Pilot Study

    Håvard Fretheim1, Oyvind Midtvedt1, Anders Heiervang Tennøe1, Henriette Didriksen1, Torhild Garen1, Espen Bækkevold1, Johannes R. Hov1, Knut EA Lundin2, Marius Trøseid1, Øyvind Molberg1 and Anna-Maria Hoffmann-Vold1, 1Oslo University Hospital, Oslo, Norway, 2Dept of gastroenterology, Oslo University Hospital, Oslo, Norway

    Background/Purpose: Up to 90% of patients with systemic sclerosis (SSc) have symptoms from the gastrointestinal (GI) tract. Earlier studies have shown a distinct alteration of…
  • Abstract Number: 1742 • 2018 ACR/ARHP Annual Meeting

    Disease-Specific Autoantibodies Associate with Remarkably Different Risk of Development of Significant Lung Fibrosis in Systemic Sclerosis

    Svetlana I. Nihtyanova1, Alper Sari2, Anna Leslie3, Voon H. Ong4 and Christopher P. Denton5, 1Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, 2Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, 3Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, 4Division of Medicine, University College London, London, United Kingdom, 5University College London, London, United Kingdom

    Background/Purpose: Pulmonary fibrosis (PF) is a leading cause of disease-related death in SSc patients. Some studies suggest that the timing of PF development differs between…
  • Abstract Number: 1878 • 2018 ACR/ARHP Annual Meeting

    Immunosuppression in Diffuse Systemic Sclerosis Improves Outcomes Using a Novel Composite Response Index

    Boyang Zheng1, Mianbo Wang2 and Murray Baron3, 1Rheumatology, McGill University Health Center (MUHC), Montreal, QC, Canada, 2Lady Davis Institute for Medical Research, Montreal, QC, Canada, 3Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada

    Background/Purpose: Diffuse systemic sclerosis (dcSSc) is a devastating multi-organ disease where the mainstay of treatment is immunosuppression. Data on these therapies are mostly based on…
  • Abstract Number: 1879 • 2018 ACR/ARHP Annual Meeting

    The Effects of Riociguat on Raynaud’s Phenomenon and Digital Ulcers in Patients with Diffuse Systemic Sclerosis: Results from the Phase IIb RISE-SSc Study

    Dinesh Khanna1, Yannick Allanore2, Christopher P. Denton3, Masataka Kuwana4, Marco Matucci-Cerinic5, Janet E. Pope6, Janethe Pena7, Kaisa Laapas8, Zhen Yao9 and Oliver Distler10, 1Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, 2Rheumatology A Department, Cochin Hospital, Paris Descartes University, Sorbonne Paris Cité, Paris, France, 3UCL Division of Medicine, Royal Free Campus, London, United Kingdom, 4Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 5Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 6Department of Medicine, University of Western Ontario, London, ON, Canada, 7Clinical Development, Bayer US LLC, Whippany, NJ, 8StatFinn Oy, Espoo, Finland, 9Bayer AG, Berlin, Germany, 10Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland

    Background/Purpose: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of pulmonary arterial hypertension associated with connective tissue disease. It was anticipated that…
  • Abstract Number: 728 • 2017 ACR/ARHP Annual Meeting

    Symptoms of Autonomic Dysfunction in Systemic Sclerosis Assessed By the Compass-31 Questionnaire

    Brittany Adler1, James Russell2, Laura K. Hummers3 and Zsuzsanna McMahan4, 1Rheumatology, Johns Hopkins University, Baltimore, MD, 2Neurology, Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, 3Medical and Rheumatology, Johns Hopkins University, Baltimore, MD, 4Department of Internal Medicine, Johns Hopkins University, Baltimore, MD

    Background/Purpose: Autonomic dysfunction is a known complication of systemic sclerosis (SSc) and can affect vascular tone, gastrointestinal (GI) motility, and heart rate and blood pressure…
  • Abstract Number: 2695 • 2017 ACR/ARHP Annual Meeting

    Latent Profile Analysis-Derived Typologies of Systemic Sclerosis Patients Using Body Image Indicators: A Scleroderma Patient-Centered Intervention Network (SPIN) Cohort Study

    Shadi Gholizadeh1, Linda Kwakkenbos2, Marie-Eve Carrier3, Sarah D. Mills1, Rina S. Fox4, Lisa Jewett2, Karen Gottesman5, Scott Roesch1, Brett D. Thombs2 and Vanessa L. Malcarne1, 1SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, 2McGill University; Lady David Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada, 3McGill University, Montreal, QC, Canada, 4Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, 5Scleroderma Foundation, Los Angeles, CA

    Background/Purpose: A common and distressing manifestation of systemic sclerosis (SSc, or scleroderma) is disfigurement in socially relevant areas of the body, including the face and…
  • Abstract Number: 733 • 2017 ACR/ARHP Annual Meeting

    Ethnic Variation in Systemic Sclerosis Morbidity and Mortality

    Sindhu Johnson1, Zareen Ahmad2 and Haifa Al Sheikh3, 1Division of Rheumatology, Toronto Western Hospital, Mount Sinai Hospital, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, 2Toronto Scleroderma Program, Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 3Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Systemic sclerosis (SSc) is an uncommon connective tissue disease characterized by pathological skin thickening and can involve multiple internal organs. Ethnic variations in SSc…
  • Abstract Number: 2696 • 2017 ACR/ARHP Annual Meeting

    Things Left Unsaid: Important Topics That Are Not Discussed between Patients with Systemic Sclerosis, Their Carers and Their Healthcare Professionals

    Christopher Denton1, Bee Laird2, Lizette Moros3 and José Luis Luna Flores4, 1Department of Rheumatology, University College London, Royal Free Hospital, London, United Kingdom, 2Reframe Research, East Sussex, United Kingdom, 3Boehringer-Ingelheim, Ingelheim, Germany, 4Boehringer Ingelheim, Ingelheim, Germany

    Background/Purpose: Systemic sclerosis (SSc) is a serious rare condition that can be complicated by internal organ damage including interstitial lung fibrosis (SSc-ILD), which is a…
  • Abstract Number: 737 • 2017 ACR/ARHP Annual Meeting

    Dynamic Prediction of Pulmonary Hypertension Development in Systemic Sclerosis Patients Using Landmark Analysis – Comparison of Two Models

    Svetlana I. Nihtyanova1, Voon H. Ong2, Emma C. Derrett-Smith3, Benjamin Schreiber4, J. Gerry Coghlan4, Bianca DeStavola5 and Christopher Denton6, 1Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, 2Rheumatology, UCL Division of Medicine, London, United Kingdom, 3Centre for Rheumatology and Connective Tissue Diseases, UCL Division of Medicine, London, United Kingdom, 4National Pulmonary Hypertension Service, Royal Free Hospital, London, United Kingdom, 5Faculty of Population Health Sciences, UCL Institute of Child Health, London, United Kingdom, 6Department of Rheumatology, University College London, Royal Free Hospital, London, United Kingdom

    Background/Purpose: Pulmonary hypertension (PH) contributes substantially to systemic sclerosis (SSc)-related morbidity and mortality. It tends to develop later in the disease, creating an opportunity for…
  • Abstract Number: 2982 • 2017 ACR/ARHP Annual Meeting

    Morbidity and Mortality of Scleroderma in African Americans

    Duncan F. Moore1, Elisabeth Kramer1, Rami Eltaraboulsi2 and Virginia D. Steen1, 1Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, 2MedStar Georgetown University Hospital, Washington, DC

    Background/Purpose: Retrospective cohorts have demonstrated that African Americans (AAs) with scleroderma are more likely to have severe disease and higher mortality than non-AAs. A prior…
  • Abstract Number: 761 • 2017 ACR/ARHP Annual Meeting

    Increased Expression of the TNF Superfamily Member LIGHT/TNFSF14 and Its Receptor (TNFRSF14) in Patients with Systemic Sclerosis

    Otylia Kowal-Bielecka1, Ewa Gindzienska-Sieskiewicz1, Oliver Distler2, Joanna Reszec3, Suzana Jordan2, Pawel Bielecki4, Andzrzej Sieskiewicz4, Agnieszka Sulik1 and Krzysztof Kowal5,6, 1Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, 2Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 3Department of Medical Pathomorphology, Department of Medical Pathomorphology, Medical University of Bialystok, Bialystok, Poland, 4Department of Otolaryngology, Medical University of Bialystok, Bialystok, Poland, 5Department of Allergology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, 6Department of Experimental Allergology and Immunology, Medical University of Bialystok, Bialystok, Poland

    Background/Purpose: The TNF Superfamily member LIGHT (TNFSF14) regulates immune response and angiogenesis. Moreover, recent studies indicate that interactions of LIGHT with its receptor, TNFRSF14, might…
  • Abstract Number: 775 • 2017 ACR/ARHP Annual Meeting

    Transcriptome Sequencing Reveals Genetic Polymorphisms Associated with Ssc Gene Expression Subtypes

    Guoshuai Cai1, Bhaven K. Mehta2, Mengqi Huang2, Jennifer Franks1, Tammara A. Wood1, Kathleen D. Kolstad3, Marianna Stark4, Antonia Valenzuela5, David Fiorentino6, Robert W. Simms7, Nicole Orzechowski8, Lorinda Chung9 and Michael L. Whitfield2, 1Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, 2Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, 3Rheumatology, Stanford University Medical Center, Stanford, CA, 4Stanford University, Stanford, CA, 5Immunology and Rheumatology, Stanford University, Palo Alto, CA, 6Department of Dermatology, Stanford University School of Medicine, Palo Alto, CA, 7Rheumatology, Boston University School of Medicine, Boston, MA, 8Dartmouth-Hitchcock Medical Center, Lebanon, NH, 9Rheumatology, Stanford University Medical Center, Palo Alto, CA

    Background/Purpose: Systemic sclerosis (SSc) is a complex disease characterized by substantial genotypic and phenotypic heterogeneity. Four molecular gene expression subsets have been identified from SSc…
  • 1
  • 2
  • 3
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology